Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL

NCT06553872 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Mantle Cell Lymphoma

Interventions

DRUG: Pirtobrutinib
DRUG: Brexucabtagene Autoleucel

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]